Intracavernosal Injection of Botulinum Toxin Type A (50 and 100 Unit) in the Treatment of Erectile Dysfunction
NCT ID: NCT03355963
Last Updated: 2019-11-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
200 participants
INTERVENTIONAL
2016-07-12
2019-02-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Patients and Methods: This study will be conducted on 200 patients diagnosed as vascular erectile dysfunction by penile color Doppler not responding to medical and injection therapy presenting to Urology department and outpatient clinic at Benha University Hospital, Andrology, Sexology \& STD's outpatient clinic, Kasr El Aini Hospitals, Cairo University.(multicentric study).
A- Inclusion criteria:
* Age between 40 to 70 years.
* Vascular ED proved by penile duplex.
* Unable to develop erections sufficient for intercourse.
* A "No" response on Sexual encounter profile questions (SEP 2 \& 3)
* Failing to respond to first line and second line treatments for Erectile Dysfunction with surgery as the only remaining treatment option.
B-Exclusion criteria:
* Significant cardiovascular disease interfering with sexual activity
* Any history of an unstable medical or psychiatric condition
* Any presence of penile anatomical abnormalities (e.g. penile fibrosis) that would significantly impair erectile function.
patients will be simply randomized into 3 equal groups, one control group and two treatment groups. Ethics committee approval and informed consent were obtained.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Botulinum Toxin for Erectile Dysfunction
NCT03102762
Intracavernosal Injection of Botulinum Toxin Type A in the Treatment of Vascular Erectile Dysfunction
NCT02584686
Intracavernous Injection of Botox 100 U for Treatment of PDE5Is Inconvenient Patients With ED
NCT04172558
Intraprostatic Injection of Botulinum Toxin A Versus Ethanol for Treatment of Patients With Benign Prostatic Hyperplasia
NCT03385161
Radiological Evaluation of the Penis Before and After a Botox Injection
NCT06044883
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
patient and methods: All patients will perform penile color Doppler evaluation to confirm a vascular etiology, a trimix solution (PGE1 10 ug + Phentolamine 1 mg + Papaverine 30 mg) was injected IC during the penile Doppler study.
The control group: received an IC 1 ml saline injection one day after the penile Doppler/trimix test.
The treatment group B: received a single IC injection of BTX-A 50 units one day after the penile Doppler/trimix test.
The treatment group C: received a single IC injection of BTX-A 100 units one day after the penile Doppler/trimix test.
Assessment for all groups was done by penile color Doppler exam, Sexual Health Inventory for men (SHIM), Sexual Encounter Profile questions 2 and 3 (SEP 2 \& SEP 3), and the global assessment question (GAQ) were completed pre-treatment and 2 weeks after treatment also, 3 and 6 months after treatment.
Procedure:
At least 1 day after the penile color Doppler test, the patient is placed in the supine position flaccid and stretched penile length and girth would be measured from tip of the penis to the pubic bone will be done. A rubber band will be applied to the base of the penis. The skin will be prepped with alcohol swabs followed by the IC injection of 50 units of BTX-A for patients in treatment group B and 100 units of BTX-A for patients in treatment group C with direct pressure will be applied for 2 minutes. The rubber band will be removed after 15 minutes.
Patients and controls will fill the Sexual Health Inventory for men (SHIM) questionnaire and answer the ,Sexual Encounter Profile questions 2 and 3 (SEP 2 \& SEP 3), and the global assessment question (GAQ) before and 2 weeks, 3 months and 6 months after treatment .
The rational for selecting the minimum 2-weeks waiting period is to give a chance for the BTX-A to reach its maximum effect. Possible Risks include pain and prolonged erections, also 3 months and 6 months after treatment do detect safety, efficacy and durability.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
The control group: received an IC 1 ml saline injection one day after the penile Doppler/trimix test.
saline injection
The control group: received an IC 1 ml saline injection one day after the penile Doppler/trimix test.
Group B
The treatment group B: received a single IC injection of BTX-A 50 units one day after the penile Doppler/trimix test.
Botulinum toxin type A 50 units
The treatment group B: received a single IC injection of BTX-A 50 units one day after the penile Doppler/trimix test.
Group C
The treatment group C:
intervention: received a single IC injection of BTX-A 100 units one day after the penile Doppler/trimix test.
Botulinum toxin type A 100 units
The treatment group C: received a single IC injection of BTX-A 100 units one day after the penile Doppler/trimix test.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
saline injection
The control group: received an IC 1 ml saline injection one day after the penile Doppler/trimix test.
Botulinum toxin type A 50 units
The treatment group B: received a single IC injection of BTX-A 50 units one day after the penile Doppler/trimix test.
Botulinum toxin type A 100 units
The treatment group C: received a single IC injection of BTX-A 100 units one day after the penile Doppler/trimix test.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
40 Years
70 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Benha University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Waleed El-Shaer, MD
Principal Investigator
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
19-09-2016
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.